Fibroblast growth factor 23 and uremic vascular calcification: is it time to escalate from biomarker status to pathogenic agent?
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24786878.
- Also identified by DOI 10.1038/ki.2013.471.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.
Medical subject headings
- Aortic Diseases
- Fibroblast Growth Factors
- Glucuronidase
- Muscle, Smooth, Vascular
- Myocytes, Smooth Muscle
- Phosphates
- Vascular Calcification